Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreati... Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 28.5714285714 | 0.035 | 0.04 | 0.03 | 239402 | 0.03887628 | DE |
| 4 | -0.025 | -35.7142857143 | 0.07 | 0.073 | 0.03 | 280315 | 0.05058816 | DE |
| 12 | 0.01 | 28.5714285714 | 0.035 | 0.135 | 0.03 | 518162 | 0.0883744 | DE |
| 26 | 0.005 | 12.5 | 0.04 | 0.135 | 0.023 | 341578 | 0.07851469 | DE |
| 52 | 0.031 | 221.428571429 | 0.014 | 0.23 | 0.013 | 593904 | 0.09727926 | DE |
| 156 | 0.035 | 350 | 0.01 | 0.23 | 0.009 | 566713 | 0.08424151 | DE |
| 260 | 0.035 | 350 | 0.01 | 0.23 | 0.009 | 566713 | 0.08424151 | DE |
Lazerator
6分前
Lazerator
6分前
moviesam
7分前
Gary Ray
7分前
mick
8分前
Foogie88
9分前
thegoodnessparadox
10分前
mick
10分前
santafe2
11分前
skitahoe
12分前
jxyzobrien
16分前
GreenBackClub
16分前
badgerkid
17分前
mick
17分前
GreenBackClub
18分前
SSKILLZ1
18分前
pinhigh
19分前
uber darthium
19分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。